Pharmarise Holdings Corporation
TSE:2796.T
536 (JPY) • At close January 14, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) JPY.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 54,466 | 52,030 | 51,608 | 52,324 | 51,030 | 51,728 | 54,562 | 52,949 | 48,511.57 | 39,506.082 | 38,221.039 | 33,357.066 | 29,607.057 | 26,825 | 23,416.897 | 20,007.602 | 18,576.785 |
| Cost of Revenue
| 46,017 | 43,896 | 43,491 | 44,256 | 43,592 | 44,386 | 46,612 | 45,731 | 41,581.659 | 33,130.3 | 32,208.283 | 28,414.86 | 25,155.326 | 22,721.754 | 20,223.484 | 17,514.333 | 16,352.66 |
| Gross Profit
| 8,449 | 8,134 | 8,117 | 8,068 | 7,438 | 7,342 | 7,950 | 7,218 | 6,929.911 | 6,375.782 | 6,012.756 | 4,942.206 | 4,451.731 | 4,103.246 | 3,193.413 | 2,493.269 | 2,224.125 |
| Gross Profit Ratio
| 0.155 | 0.156 | 0.157 | 0.154 | 0.146 | 0.142 | 0.146 | 0.136 | 0.143 | 0.161 | 0.157 | 0.148 | 0.15 | 0.153 | 0.136 | 0.125 | 0.12 |
| Reseach & Development Expenses
| 12 | 13 | 10 | 21 | 9 | 13 | 13 | 8 | 7.643 | 7 | 13 | 14 | 0 | 0 | 0 | 0 | 0 |
| General & Administrative Expenses
| 0 | 0 | 0 | 292 | 271 | 368 | 349 | 359 | 427 | 458 | 454 | 362 | 0 | 0 | 0 | 0 | 0 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 3,374 | 3,199 | 3,298 | 3,198 | 3,227 | 2,494.932 | 1,937 | 1,899 | 1,517 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 4,371 | 3,728 | 3,525 | 3,666 | 3,470 | 3,666 | 3,547 | 3,586 | 2,921.932 | 2,395 | 2,353 | 1,879 | 0 | 0 | 0 | 0 | 0 |
| Other Expenses
| 3,150 | 32 | -7 | 21 | 24 | -15 | 6,771 | 96 | 76.504 | 63.253 | -103.169 | 28.38 | -70.36 | -39.446 | -115.221 | -55.311 | -64.527 |
| Operating Expenses
| 7,533 | 6,695 | 6,596 | 6,821 | 6,402 | 6,702 | 6,771 | 6,775 | 6,116.757 | 5,232.462 | 4,440.072 | 3,530.489 | 2,794.426 | 2,606.466 | 2,210.57 | 1,953.429 | 1,730.047 |
| Operating Income
| 916 | 1,438 | 1,520 | 1,246 | 1,034 | 640 | 1,179 | 442 | 813.154 | 1,143.319 | 1,572.683 | 1,411.716 | 1,657.304 | 1,496.779 | 982.842 | 539.839 | 494.077 |
| Operating Income Ratio
| 0.017 | 0.028 | 0.029 | 0.024 | 0.02 | 0.012 | 0.022 | 0.008 | 0.017 | 0.029 | 0.041 | 0.042 | 0.056 | 0.056 | 0.042 | 0.027 | 0.027 |
| Total Other Income Expenses Net
| -773 | -389 | -198 | -44 | -215 | -240 | -765 | -441 | 212 | -199.865 | -416.594 | 219.431 | -221.78 | -324.636 | -402.197 | -97.221 | -231.631 |
| Income Before Tax
| 143 | 1,049 | 1,322 | 1,202 | 819 | 400 | 414 | 1 | 1,024.793 | 943.454 | 1,156.089 | 1,631.147 | 1,435.524 | 1,172.143 | 580.645 | 442.373 | 262.446 |
| Income Before Tax Ratio
| 0.003 | 0.02 | 0.026 | 0.023 | 0.016 | 0.008 | 0.008 | 0 | 0.021 | 0.024 | 0.03 | 0.049 | 0.048 | 0.044 | 0.025 | 0.022 | 0.014 |
| Income Tax Expense
| 485 | 702 | 863 | 782 | 238 | 409 | 622 | 251 | 655.488 | 714.903 | 778.88 | 666.964 | 739.735 | 598.675 | 296.938 | 216.96 | 161.189 |
| Net Income
| -351 | 333 | 447 | 426 | 577 | 23 | -208 | 7 | 382.195 | 227.892 | 369.094 | 958.001 | 685.818 | 562.978 | 276.576 | 222.508 | 96.525 |
| Net Income Ratio
| -0.006 | 0.006 | 0.009 | 0.008 | 0.011 | 0 | -0.004 | 0 | 0.008 | 0.006 | 0.01 | 0.029 | 0.023 | 0.021 | 0.012 | 0.011 | 0.005 |
| EPS
| -33.35 | 35.42 | 47.9 | 45.78 | 61.03 | 2.51 | -23.01 | 0.85 | 42.44 | 25.31 | 46.55 | 127.73 | 91.44 | 88.78 | 43.12 | 103.06 | 14.99 |
| EPS Diluted
| -33.35 | 26.86 | 36.22 | 34.59 | 46.32 | 2.12 | -23.01 | 0.83 | 41.55 | 24.99 | 46.31 | 127.73 | 91.44 | 88.78 | 43.12 | 103.06 | 14.99 |
| EBITDA
| 2,086 | 2,663 | 2,829 | 2,591 | 2,264 | 1,863 | 2,507 | 1,776 | 2,384.612 | 2,278.858 | 2,440.812 | 2,645.602 | 2,243.147 | 1,908.77 | 1,129.014 | 912.821 | 790.243 |
| EBITDA Ratio
| 0.038 | 0.052 | 0.055 | 0.05 | 0.044 | 0.035 | 0.046 | 0.033 | 0.042 | 0.059 | 0.066 | 0.067 | 0.077 | 0.078 | 0.056 | 0.044 | 0.043 |